PepGen Inc. shares plunged about 65% after mixed Phase 2 data for PGN-EDODM1 in DM1, with no functional improvement at 5 ...

AI is not overhyped. The potential requires equal attention to the less glamorous but more important role of data management.

The data reveal from the phase 1 INLIGHT study of WVE-007 – an oligonucleotide-based gene-silencing drug designed to switch ...

The lack of effect on different measures of coronary plaque reinforce the need for a large CV outcomes trial in these ...

China NMPA accepts for review GSK’s NDA for bepirovirsen, an investigational ASO to treat adults with chronic hepatitis B: London, UK Tuesday, March 31, 2026, 16:00 Hrs [IST] GS ...

New research from Washington University School of Medicine in St. Louis adds to growing evidence that helping brain cells ...

Kardigan’s tonlamarsen reduced a key biomarker for hypertension in a phase 2 trial, but missed the study’s other goal of significantly reducing blood pressure. The biotech evaluated monthly 90 mg ...

Two former US Food and Drug Administration (FDA) officials have commented on and proposed changes to the agency’s recent draft guidance on the development of a plausible mechanism framework for ...

After a surprise rejection in September last year, the FDA has signed off on a high-dose formulation of Biogen’s spinal muscular atrophy drug Spinraza. The approval, announced Monday, will allow a ...

At DCAT Week 2026, Contract Pharma spoke with Aniel Khubchandani, Aragen Life Sciences CEO, Development & Manufacturing ...

GSK (GSK.L) on Monday unveiled regulatory updates for its drug portfolio in China, with its asthma medication Exdensur approved and its chronic hepatitis B treatment bepirovirsen accepted for review.

The FDA has approved a high-dose regimen of Biogen’s nusinersen (SPINRAZA) for the treatment of spinal muscular atrophy. 1 ...